Cathie Wood Boosts Biotech, Fintech Holdings While Trimming AI Stock amid Market Volatility

Cathie Wood's ARK Invest is actively reshaping its portfolio in 2025, focusing on biotech, fintech, and AI sectors while trimming some high-performing stocks. Wood notably invested $19.2 million in Intellia Therapeutics, betting on transformative CRISPR gene-editing therapies with upcoming data milestones, signaling confidence in a potential biotech re-rating. Simultaneously, ARK Invest increased stakes in market laggards like Amazon, DraftKings, and Block, the latter reflecting Wood's bullish stance on crypto and fintech innovation despite recent market volatility. While ARK trimmed its position in Palantir, a leading AI stock with substantial gains, the firm remains bullish on AI's growth potential and diversified its holdings by adding shares in other tech and biotech companies. These moves illustrate Wood's strategic balance between capturing emerging innovation and managing stretched valuations amid a volatile market environment. Overall, ARK's portfolio adjustments highlight a methodical approach to leverage disruptive innovation themes for the latter half of the year.